title: Management of neuroleptic malignant syndrome--a series of eight cases.
abstract: Neuroleptic Malignant Syndrome (NMS) is a rare and life threatening complication of treatment with Neuroleptic medication. Phenothiazine and butyrophenones are most frequently implicated in this syndrome even though there are case reports with other drugs. In this paper we describe the classical presentation of this syndrome in eight cases who had been on either a butyrophenone, a phenothiazine or a combination of these drugs. In addition some of our patients were also on either Lithium and/or Amitrytiline for control of depressive symptoms. Fever, muscule rigidity and elevated CPK are the important criteria for diagnosis and they were noted in all our patients. In addition four of our patients fulfilled five of the six minor criteria laid down by Levenson. Both Sinemet and Bromocriptine were found to be effective in the treatment of seven of the eight cases. However treatment with Dantroline sodium was associated with severe muscle wasting in one of our cases and the drug had to be discontinued. Two of our patients developed suspected myoglobinuria with dark coloured urine and progressive renal failure. One patient died after development of renal failure, pulmonary edema and hyperkalemia as a consequence of this disorders.
authors.affiliation: Department of Medicine CMCH, Vellore.
authors.forename: T
authors.initials: T
authors.lastname: Kurien
authors.forename: K K
authors.initials: KK
authors.lastname: Rajeev
authors.forename: O C
authors.initials: OC
authors.lastname: Abraham
authors.forename: S
authors.initials: S
authors.lastname: Archana
authors.forename: A M
authors.initials: AM
authors.lastname: Cherian
mesh_terms: D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D002230:Carbidopa / Q000627:therapeutic use*; D003620:Dantrolene / Q000009:adverse effects / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007194:India / Q000453:epidemiology; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy* / Q000453:epidemiology
chemical_list: D015259:Dopamine Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D001971:Bromocriptine; D007980:Levodopa; D003620:Dantrolene; D002230:Carbidopa